Vixarelimab
CAS No. 2243320-83-2
Vixarelimab( —— )
Catalog No. M36781 CAS No. 2243320-83-2
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody with affinity for the beta chain of the OSM receptor, inhibiting IL-31 and OSM signaling.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 947 | In Stock |
|
| 10MG | 1511 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVixarelimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionVixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody with affinity for the beta chain of the OSM receptor, inhibiting IL-31 and OSM signaling.
-
DescriptionVixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorInterleukin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2243320-83-2
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Carl D Richards, et al. Oncostatin M Induction of Monocyte Chemoattractant Protein 1 is Inhibited by Anti-oncostatin M Receptor Beta Monoclonal Antibody KPL-716. Acta Derm Venereol. 2020 Jul 2;100(14):adv00197.?
molnova catalog
related products
-
Prepro-Neuromedin S ...
Prepro-Neuromedin S (70-103) (human)
-
Guaiacin
(+)-Guaiacin has significant neuroprotective, and anti-inflammatory activities, it can inhibit cyclooxygenase (COX)-1 and COX-2.
-
Boc-Cholecystokinin ...
Boc-Cholecystokinin Octapeptide (desulfated)
Cart
sales@molnova.com